We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
Our goal is to be one of the world’s most innovative, best performing and trusted healthcare companies.
Our strategy is to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our three global businesses, scientific and technical know-how and talented people.
Our values and expectations are at the heart of everything we do and form an important part of our culture.
Our values are Patient focus, Transparency, Respect, Integrity.
Our expectations are Courage, Accountability, Development, Teamwork.
GlaxoSmithKline Plc was formed in 2000 as a result of a merger between Glaxo Wellcome Plc and SmithKline Beecham Plc, although our history can be traced back much further than that to London’s Plough Court Pharmacy in the 1700s.
In March 2015, our global business completed a three-part transaction with Novartis which reshapes our business.
We acquired Novartis’s vaccines business (excluding influenza vaccines) and combined our Consumer Healthcare businesses to create a new company. By substantially strengthening Vaccines and Consumer Healthcare, we can deliver far-reaching benefits to patients and consumers, and further value to shareholders. In addition, Novartis acquired our marketed Oncology portfolio.
GlaxoSmithKline Consumer Nigeria Plc was incorporated in Nigeria on 23rd June 1971 and commenced business on 1st July 1972, under the name Beecham Limited. Its Head office is located at 1 Industrial Avenue, Ilupeju, Lagos. The Company was quoted on the Nigerian Stock Exchange in 1977. In 1982, in order to expand our operations in the country, an ultra-modern drinks factory was established in Agbara Industrial Estate, Ogun State, which has since been expanded to include facilities to manufacture Oral Healthcare (OHC) and Wellness products. In line with our commitment to continuous improvement, we regularly update our facilities to meet the ever-increasing demands of our consumers.
On the 30th September 2016, the GSK Nigeria business officially closed a transaction for the divestment of a part of its business. The transaction involved the divestment to Suntory Beverage & Food Ltd the GSK Drinks bottling and distribution business and other assets including the factory appropriated to and utilised for the Drinks Business. The business was formally handed over to the new owners on 1st October 2016.
One of the objectives of the divestment was to allow the Nigeria business to focus on the same consumer healthcare portfolio as the parent group.
Following this handover, the new GSK Consumer Healthcare Company (retained business) includes Wellness (OTC), Oral Healthcare and Nutrition categories. The retained brands include Sensodyne, Macleans, Panadol, Horlicks, Andrews Liver Salts, Voltaren, Otrivin and CAC 1000.
GSK Consumer Nigeria Plc continues to be listed on the Nigerian Stock Exchange (NSE).
GSK’s Contract Manufacturing Agreement
In April 2019, GSK Nigeria announced a contract manufacturing agreement with Fidson Health Care Plc. With this decision, Fidson Healthcare PLC will contract manufacture five (5) formulations (“Products”) for GSK Consumer Nigeria Plc. The number of formulations may potentially increase as the contract agreement progresses.